WHO suggestions for stemming HIV epidemics

1 December 2008

A group of specialists in the World Health Organization have developed a mathematical model, published in The Lancet, to stimulate discussion, debate and further research relating to HIV/AIDS. The model suggests that using annual, universal voluntary HIV testing followed by immediate ART (irrespective of clinical stage or CD4 count) reduces new cases by 95% within 10 years.

The authors of the study also report that universal voluntary testing followed by immediate ART could have additional public health benefits, including reducing the incidence of tuberculosis and the transmission of HIV from mother to child. Additionally, the model suggests that there could be a significant reduction of HIV-related morbidity and mortality in resource-limited countries with generalized HIV epidemics.

The current WHO policy on treatment involves voluntary testing and clinical and/or immunological evaluation (eg, CD4 count) to determine eligibility for treatment with antiretrovirals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight